https://orcid.org/0000-0002-7591-921X
References
- El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12(1):4–8. doi:10.1097/00055735-200102000-00002
- Porela-Tiihonen S, Kokki H, Kaarniranta K, Kokki M. Recovery after cataract surgery. Acta Ophthalmol. 2016;94(Suppl 2):1–34. doi:10.1111/aos.13055
- Shah SM, Spalton DJ. Changes in anterior chamber flare and cells following cataract surgery. Br J Ophthalmol. 1994;78(2):91–94. doi:10.1136/bjo.78.2.91
- Shah TJ, Conway MD, Peyman GA. Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy. Clin Ophthalmol. 2018;12:2223–2235. doi:10.2147/OPTH.S165722
- Grzybowski A, Brockmann T, Kanclerz P, Pleyer U. Dexamethasone intraocular suspension: a long-acting therapeutic for treating inflammation associated with cataract surgery. J Ocul Pharmacol Ther. 2019;35(10):525–534. doi:10.1089/jop.2019.0072
- AAO PPP Cataract/Anterior Segment Panel, Hoskins Center for Quality Eye Care. Cataract in the adult eye PPP; 2016. Available from: https://www.aao.org/preferred-practice-pattern/cataract-in-adult-eye-ppp-2016. Accessed September 15, 2020.
- Schwartz GF, Hollander DA, Williams JM. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2013;29(11):1515e1522. doi:10.1185/03007995.2013.833898
- An JA, Kasner O, Samek DA, Lévesque V. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014;40(11):1857–1861. doi:10.1016/j.jcrs.2014.02.037
- Osher RH, Weinstock RJ. Dexamethasone intraocular suspension 9% in the capsular bag [published online ahead of print, 2020 Nov 27]. J Cataract Refract Surg. 2020. doi:10.1097/j.jcrs.0000000000000458
- Donnenfeld E, Holland E. Dexamethasone intracameral drug-delivery suspension for inflammation associated with cataract surgery: a randomized, placebo-controlled, Phase III trial. Ophthalmology. 2018;125(6):799–806. doi:10.1016/j.ophtha.2017.12.029
- Donnenfeld ED, Solomon KD, Matossian C. Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study. J Cataract Refract Surg. 2018;44(10):1236–1246. doi:10.1016/j.jcrs.2018.07.015
- Hovanesian JA, Donnenfeld ED. Patient-reported tolerance and satisfaction with intraocular administration of dexamethasone and moxifloxacin vs a topical regimen. Presented at: American Society of Cataract and Refractive Surgery Virtual Annual Meeting; May 16–17; 2020.
- Matossian C, Hovanesian J, Bacharach J, Paggiarino D, Patel K. Impact of dexamethasone intraocular suspension 9% on intraocular pressure following routine cataract surgery: post hoc analysis. J Cataract Refract Surg. 2020. doi:10.1097/j.jcrs.0000000000000363
- Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774. doi:10.1007/s12325-018-0805-y
- Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516.